Firalis is a biotechnology company with an acknowledged leadership and expertise in the field of biomarkers (BM), in particular within the cardiovascular field.
Firalis develops and markets biomarkers and biomarker-based diagnostic tools such as ELISA assay kits, for pre-clinical and clinical applications, including:
• Safety BMs for drug-induced cardiovascular injuries
• Diagnostic/prognostic BMs for vasculitis and myocardial infarction
• Theranostic and companion BMs for CV related drugs
Firalis owes its leading position to below major advantages:
• Pioneer expertise in the development and "clinical qualification" of new innovative biomarkers
• A large, well-established network of international centers of excellence, large biobank initiatives, acknowledged clinicians, major players from pharmaceutical industry and several private biotech companies (SMEs) that are working in complementary fields.
• A unique IP position on biomarkers of drug-induced cardiovascular safety.
• ISO:9001 and ISO:13485 certified laboratories
• ISO:17025 accredited testing activities
• An established GLP/GCLP & NF S96-900 compliant work environment for biomarker assay development and testing activities
• A robust technology platform, including multiplex arrays
Follow us on:
Linkedin : www.linkedin.com/company/firalis-sas
Twitter : https://twitter.com/FiralisGroup
Location: France, Grand Est, Huningue
Member count: 11-50
Phone: +33 3 89 91 13 20
Founded date: 2008
Investors 2
Date | Name | Website |
- | Auriga Par... | auriga.vc |
- | Capital Gr... | capitalgra... |